Therapeutic effect of anti-nucleokine monoclonal antibody on ischemic brain infarction

Shuji Mori, Keyue Liu, Hideo K. Takahashi, Masahiro Nishibori

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Ischemic brain infarction is high among th causes of death in Japan, and the medical and social burden by severe sequela is also extremely serious. In this symposium, we show that treatment with anti-high mobility group box 1 (HMGB1) monoclonal antibody (mAb) remarkably ameliorated brain infarction induced by 2-hour occlusion of the middle cerebral artery in rats, even when the mAb was administered after the start of reperfusion. Whereas HMGB1 is usually localized in nucleus, after stimulation it is secreted into extracellular space by an unknown non-classical pathway, and exhibits an inflammatory cytokine-like activity. Treatment with mAb reduced infarct size, and the accompanying neurological deficits in locomotor function were significantly improved. In addition, some biochemical markers such as permeability of the blood-brain barrier, the expression of tumor necrosis factor-alfa, inducible nitric oxide synthase and matrix metalloproteinase-9 were altered by mAb injection. These findings indicate the usefulness of HMGB1 as a novel therapeutic to target ischemic stroke.

Original languageEnglish
Pages (from-to)25-31
Number of pages7
JournalYakugaku Zasshi
Volume129
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Brain Infarction
Therapeutic Uses
Monoclonal Antibodies
Middle Cerebral Artery Infarction
Matrix Metalloproteinase 9
Extracellular Space
Nitric Oxide Synthase Type II
Blood-Brain Barrier
Reperfusion
Cause of Death
Permeability
Japan
Therapeutics
Tumor Necrosis Factor-alpha
Biomarkers
Stroke
Cytokines
Injections

Keywords

  • Antibody therapeutics
  • Ischemic brain infarction
  • Target therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Therapeutic effect of anti-nucleokine monoclonal antibody on ischemic brain infarction. / Mori, Shuji; Liu, Keyue; Takahashi, Hideo K.; Nishibori, Masahiro.

In: Yakugaku Zasshi, Vol. 129, No. 1, 01.2009, p. 25-31.

Research output: Contribution to journalArticle

Mori, Shuji ; Liu, Keyue ; Takahashi, Hideo K. ; Nishibori, Masahiro. / Therapeutic effect of anti-nucleokine monoclonal antibody on ischemic brain infarction. In: Yakugaku Zasshi. 2009 ; Vol. 129, No. 1. pp. 25-31.
@article{0d0375b2ac344cd6afb993fd95db8db7,
title = "Therapeutic effect of anti-nucleokine monoclonal antibody on ischemic brain infarction",
abstract = "Ischemic brain infarction is high among th causes of death in Japan, and the medical and social burden by severe sequela is also extremely serious. In this symposium, we show that treatment with anti-high mobility group box 1 (HMGB1) monoclonal antibody (mAb) remarkably ameliorated brain infarction induced by 2-hour occlusion of the middle cerebral artery in rats, even when the mAb was administered after the start of reperfusion. Whereas HMGB1 is usually localized in nucleus, after stimulation it is secreted into extracellular space by an unknown non-classical pathway, and exhibits an inflammatory cytokine-like activity. Treatment with mAb reduced infarct size, and the accompanying neurological deficits in locomotor function were significantly improved. In addition, some biochemical markers such as permeability of the blood-brain barrier, the expression of tumor necrosis factor-alfa, inducible nitric oxide synthase and matrix metalloproteinase-9 were altered by mAb injection. These findings indicate the usefulness of HMGB1 as a novel therapeutic to target ischemic stroke.",
keywords = "Antibody therapeutics, Ischemic brain infarction, Target therapy",
author = "Shuji Mori and Keyue Liu and Takahashi, {Hideo K.} and Masahiro Nishibori",
year = "2009",
month = "1",
doi = "10.1248/yakushi.129.25",
language = "English",
volume = "129",
pages = "25--31",
journal = "Yakugaku Zasshi",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "1",

}

TY - JOUR

T1 - Therapeutic effect of anti-nucleokine monoclonal antibody on ischemic brain infarction

AU - Mori, Shuji

AU - Liu, Keyue

AU - Takahashi, Hideo K.

AU - Nishibori, Masahiro

PY - 2009/1

Y1 - 2009/1

N2 - Ischemic brain infarction is high among th causes of death in Japan, and the medical and social burden by severe sequela is also extremely serious. In this symposium, we show that treatment with anti-high mobility group box 1 (HMGB1) monoclonal antibody (mAb) remarkably ameliorated brain infarction induced by 2-hour occlusion of the middle cerebral artery in rats, even when the mAb was administered after the start of reperfusion. Whereas HMGB1 is usually localized in nucleus, after stimulation it is secreted into extracellular space by an unknown non-classical pathway, and exhibits an inflammatory cytokine-like activity. Treatment with mAb reduced infarct size, and the accompanying neurological deficits in locomotor function were significantly improved. In addition, some biochemical markers such as permeability of the blood-brain barrier, the expression of tumor necrosis factor-alfa, inducible nitric oxide synthase and matrix metalloproteinase-9 were altered by mAb injection. These findings indicate the usefulness of HMGB1 as a novel therapeutic to target ischemic stroke.

AB - Ischemic brain infarction is high among th causes of death in Japan, and the medical and social burden by severe sequela is also extremely serious. In this symposium, we show that treatment with anti-high mobility group box 1 (HMGB1) monoclonal antibody (mAb) remarkably ameliorated brain infarction induced by 2-hour occlusion of the middle cerebral artery in rats, even when the mAb was administered after the start of reperfusion. Whereas HMGB1 is usually localized in nucleus, after stimulation it is secreted into extracellular space by an unknown non-classical pathway, and exhibits an inflammatory cytokine-like activity. Treatment with mAb reduced infarct size, and the accompanying neurological deficits in locomotor function were significantly improved. In addition, some biochemical markers such as permeability of the blood-brain barrier, the expression of tumor necrosis factor-alfa, inducible nitric oxide synthase and matrix metalloproteinase-9 were altered by mAb injection. These findings indicate the usefulness of HMGB1 as a novel therapeutic to target ischemic stroke.

KW - Antibody therapeutics

KW - Ischemic brain infarction

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=58149508350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149508350&partnerID=8YFLogxK

U2 - 10.1248/yakushi.129.25

DO - 10.1248/yakushi.129.25

M3 - Article

C2 - 19122433

AN - SCOPUS:58149508350

VL - 129

SP - 25

EP - 31

JO - Yakugaku Zasshi

JF - Yakugaku Zasshi

SN - 0031-6903

IS - 1

ER -